VAXCYTE, INC. General and Administrative Expense
VAXCYTE, INC. (PCVX) reported General and Administrative Expense of $34.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-05
- VAXCYTE, INC. general and administrative expense for the quarter ending 2026-06-30 was $34.92M, a 9.00% increase year-over-year.
- VAXCYTE, INC. general and administrative expense for the quarter ending 2026-03-31 was $33.07M, a 1.26% increase year-over-year.
- VAXCYTE, INC. general and administrative expense for the quarter ending 2025-12-31 was $32.22M, a 12.85% increase year-over-year.
- VAXCYTE, INC. general and administrative expense for the quarter ending 2025-09-30 was $32.45M, a 41.15% increase year-over-year.
- VAXCYTE, INC. general and administrative expense for fiscal 2025 was $129.37M, a 39.25% increase from fiscal 2024.
- VAXCYTE, INC. general and administrative expense for fiscal 2024 was $92.90M, a 53.05% increase from fiscal 2023.
- VAXCYTE, INC. general and administrative expense for fiscal 2023 was $60.70M, a 52.47% increase from fiscal 2022.
- VAXCYTE, INC. general and administrative expense for fiscal 2022 was $39.81M, a 57.61% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.92M 10-Q · filed 2026-08-05 | $68.00M 10-Q · filed 2026-08-05 | $100.22M derived: sum of 3 quarters · filed 2026-08-05 | $132.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $33.07M 10-Q · filed 2026-05-06 | $65.29M derived: sum of 2 quarters · filed 2026-05-06 | $97.74M derived: sum of 3 quarters · filed 2026-05-06 | $129.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $32.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $64.67M derived: sum of 2 quarters · filed 2026-02-24 | $96.71M derived: sum of 3 quarters · filed 2026-08-05 | $129.37M 10-K · filed 2026-02-24 |
| 2025-09-30 | $32.45M 10-Q · filed 2025-11-04 | $64.49M derived: sum of 2 quarters · filed 2026-08-05 | $97.15M 10-Q · filed 2025-11-04 | $125.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $32.04M 10-Q · filed 2026-08-05 | $64.70M 10-Q · filed 2026-08-05 | $93.25M derived: sum of 3 quarters · filed 2026-08-05 | $116.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $32.66M 10-Q · filed 2026-05-06 | $61.21M derived: sum of 2 quarters · filed 2026-05-06 | $84.20M derived: sum of 3 quarters · filed 2026-05-06 | $105.68M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $28.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $51.54M derived: sum of 2 quarters · filed 2026-02-24 | $73.02M derived: sum of 3 quarters · filed 2026-02-24 | $92.90M 10-K · filed 2026-02-24 |
| 2024-09-30 | $22.99M 10-Q · filed 2025-11-04 | $44.46M derived: sum of 2 quarters · filed 2025-11-04 | $64.35M 10-Q · filed 2025-11-04 | $81.87M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $21.47M 10-Q · filed 2025-08-06 | $41.36M 10-Q · filed 2025-08-06 | $58.88M derived: sum of 3 quarters · filed 2026-02-24 | $74.49M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $19.89M 10-Q · filed 2025-05-07 | $37.41M derived: sum of 2 quarters · filed 2026-02-24 | $53.02M derived: sum of 3 quarters · filed 2026-02-24 | $67.47M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $17.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $33.13M derived: sum of 2 quarters · filed 2026-02-24 | $47.59M derived: sum of 3 quarters · filed 2026-02-24 | $60.70M 10-K · filed 2026-02-24 |
| 2023-09-30 | $15.61M 10-Q · filed 2024-11-05 | $30.06M derived: sum of 2 quarters · filed 2024-11-05 | $43.17M 10-Q · filed 2024-11-05 | $55.13M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $14.46M 10-Q · filed 2024-08-06 | $27.57M 10-Q · filed 2024-08-06 | $39.52M derived: sum of 3 quarters · filed 2025-02-25 | $50.42M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $13.11M 10-Q · filed 2024-05-08 | $25.06M derived: sum of 2 quarters · filed 2025-02-25 | $35.96M derived: sum of 3 quarters · filed 2025-02-25 | $45.38M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $11.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $22.85M derived: sum of 2 quarters · filed 2025-02-25 | $32.27M derived: sum of 3 quarters · filed 2025-02-25 | $39.81M 10-K · filed 2025-02-25 |
| 2022-09-30 | $10.90M 10-Q · filed 2023-11-06 | $20.32M derived: sum of 2 quarters · filed 2023-11-06 | $27.86M 10-Q · filed 2023-11-06 | $34.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $9.42M 10-Q · filed 2023-08-08 | $16.96M 10-Q · filed 2023-08-08 | $23.73M derived: sum of 3 quarters · filed 2024-02-27 | $30.25M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $7.54M 10-Q · filed 2023-05-08 | $14.31M derived: sum of 2 quarters · filed 2024-02-27 | $20.84M derived: sum of 3 quarters · filed 2024-02-27 | $26.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $6.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $13.29M derived: sum of 2 quarters · filed 2024-02-27 | $19.37M derived: sum of 3 quarters · filed 2024-02-27 | $25.26M 10-K · filed 2024-02-27 |
| 2021-09-30 | $6.52M 10-Q · filed 2022-11-07 | $12.60M derived: sum of 2 quarters · filed 2022-11-07 | $18.49M 10-Q · filed 2022-11-07 | $23.28M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $6.08M 10-Q · filed 2022-08-08 | $11.96M 10-Q · filed 2022-08-08 | $16.76M derived: sum of 3 quarters · filed 2022-08-08 | $21.65M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $5.88M 10-Q · filed 2022-05-09 | $10.68M derived: sum of 2 quarters · filed 2022-05-09 | $15.57M derived: sum of 3 quarters · filed 2022-05-09 | $18.62M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $4.79M 10-K · filed 2021-03-29 | $9.69M derived: sum of 2 quarters · filed 2021-11-10 | $12.74M derived: sum of 3 quarters · filed 2021-11-10 | $16.02M 10-K · filed 2023-02-27 |
| 2020-09-30 | $4.90M 10-Q · filed 2021-11-10 | $7.94M derived: sum of 2 quarters · filed 2021-11-10 | $11.22M 10-Q · filed 2021-11-10 | $13.68M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $3.05M 10-Q · filed 2021-08-11 | $6.33M 10-Q · filed 2021-08-11 | $8.78M derived: sum of 3 quarters · filed 2021-08-11 | $11.29M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $3.28M 10-Q · filed 2021-05-11 | $5.74M derived: sum of 2 quarters · filed 2021-05-11 | $8.25M derived: sum of 3 quarters · filed 2021-05-11 | $10.51M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $2.46M 10-K · filed 2021-03-29 | $4.97M derived: sum of 2 quarters · filed 2021-03-29 | $7.23M derived: sum of 3 quarters · filed 2021-03-29 | $8.55M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.51M 10-K · filed 2021-03-29 | $4.77M derived: sum of 2 quarters · filed 2021-03-29 | $6.09M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $2.26M 10-K · filed 2021-03-29 | $3.58M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $1.32M 10-K · filed 2021-03-29 | |||
| 2018-12-31 | $5.39M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |